GeneQuine is focused on developing gene therapy for the treatment of musculoskeletal disorders. The company’s management and scientists are biopharma and gene therapy experts, driven by the potential that gene therapy holds to revolutionize the treatment of chronic, musculoskeletal disorders. GeneQuine’s management is supported by a strong advisory board with science, pharma and venture capital backgrounds.

Management

Kilian Guse

Kilian Guse, PhD

CEO, Co-Founder

Dr. Guse is the CEO and co-founder of GeneQuine. He has more than 15 years experience in gene therapy research and development and is author of more than 30 scientific publications in international, peer-reviewed journals and book chapters on this topic.

More

Stanislav Plutizki

Stanislav Plutizki, PhD

COO, Co-Founder

Prior to co-founding and working for GeneQuine, Dr. Plutizki was international medical manager at the regulatory and global medical marketing department at Berlin Chemie AG (Menarini Group), Berlin, Germany, where he was responsible for medical and scientific management of a large product portfolio.

More

Advisory Board

Bernhard J. Kirschbaum

Bernhard J. Kirschbaum, PhD

Chairman of the Board

Dr. Kirschbaum is a board member of several biotech companies and has 20 years of experience in R&D of global international pharma companies at Hoechst Maron Roussel, Aventis, Sanofi-Aventis, and Merck Serono, and was in his last position Executive Vice President, Global Research & Early Development and member of the board at Merck Serono.

More

Amel Tounsi

Amel Tounsi, PhD

Dr. Tounsi is a scientist with immunology and cellular biology background, experienced in cell therapy development from R&D to clinical phase, business development and company Development strategy. Continuous learning and training on the managerial and entrepreneurial aspect of the biotech industry is her drive.

More

Martin Pfister

Martin Pfister, PhD

Dr. Martin Pfister studied medicine and pharmacy at the University of Greifswald, Germany, and New York University, USA, and received his doctorate in immunology. He worked in various academic laboratories. Since 2000 he has been active in the start-up scene.

More

Ronald J. Ellis, Jr.

Ronald J. Ellis, Jr., DO

Ron Ellis brings over 20 years of healthcare experience in medicine, clinical research, equity research and institutional investing. Dr. Ellis is currently Senior Vice President of Corporate Strategy & Business Development at Pacira BioSciences, Inc., where he leads the company’s efforts in strategy, licensing and acquisition.

More

Peter Johann

Peter Johann, PhD

Dr. Johann is the founder, Chairman and CEO of Lumendi Ltd., an innovative medtech company focusing on devices enabling/improving endoluminal gastrointestinal interventions. He also is a Managing General Partner of NGN Capital, a healthcare venture capital investor. Dr. Johann had several successful IPOs and M&A transactions in his investment portfolio.

More

Gencer Sahin

Gencer Sahin

Observer

Gencer Sahin is Head of Investments at the venture capital fund Innovationsstarter Fonds Hamburg GmbH, Hamburg, Germany. He studied industrial engineering, has several years of experience in consulting, and has been active in the start-up scene since 2012.

More

Scientific Advisory Board

Yves Henrotin

Yves Henrotin, Prof.

Clinical and Scientific Advisor

Professor of Pathology, Physical Therapy and Rehabilitation and Director of the Bone and Cartilage Research Unit at the University of Liège, Belgium; President of Osteoarthritis Foundation.

More

Collaborations

Baylor College of Medicine

Baylor College of Medicine

Baylor College of Medicine (BCM), located in Houston, Texas, USA is one of the leading medical schools and biomedical research institutes in the country.

More

Flexion Therapeutics, Inc.

Flexion Therapeutics, Inc.

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis.

More